Heart Test Laboratories announced the podium presentation of a study utilizing its MyoVista wavECG device at the 18th World Congress of Anesthesiologists in Singapore. The author of the study stated in his presentation, “In our cohort of mixed surgical population, the MyoVista wavECG was useful as a screening tool with 100% sensitivity. Based on these findings, 25 of the 60 non-LVDD patients could be safely excluded from referral to preoperative echocardiography. Also, MyoVista wavECG can raise red flag for more detailed examination by expert cardiologists when findings are positive.” The author concluded, “The use of MyoVista wavECG for screening preoperative patients for LVDD to reduce the burden of referrals to preoperative echocardiography may be feasible and should be investigated further.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HSCS:
- HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
- Heart Test Laboratories price target lowered to 35c from $3 at Maxim
- HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
- HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
- Heart Test Laboratories announces publication on use of MyoVista technology